Because there was no correlation between the presence of PD-L1 expression and the therapeutic effect of nivolumab in patients diagnosed with dMMR in the Checkmate-142 study [60], PD-1/PD-L1 inhibitors are expected to be effective even when the tumor is negative for PD-L1 expression, as long as it is dMMR. This evidence concerns the gene PDCD1 and neoplasm.